Unmasking Multiple Sclerosis

Unmasking Multiple Sclerosis

Multiple SCLEROSIS Awareness March is Multiple Sclerosis (MS) Awareness Month, so this WEEKLY takes a look at the science behind the disease and some of the treatments developed for it. MS typically occurs in susceptible individuals between the ages of 20 and 50, and...
RNA Therapeutics March Onward

RNA Therapeutics March Onward

Taking Steps With Antisense With their high specificity and relative low manufacturing cost, RNA therapeutics may be tomorrow’s biotech sweetheart. In fact, chances are good that previously “undruggable” targets that cannot be accessed by small or large molecule...
New Hope For Spinal Muscular Atrophy

New Hope For Spinal Muscular Atrophy

FIRST THERAPY APPROVED FOR SMA Squeaking by on December 23rd as the last new drug approval of 2016, Biogen’s (Cambridge, MA) Spinraza now provides hope for the thousands of families affected by a debilitating neuromuscular disorder known as spinal muscular atrophy...
Unwiring The Biology Of Fibrosis

Unwiring The Biology Of Fibrosis

Fibrotic Disease Innovations Fibrotic diseases — organ and tissue disorders that occur as a result of the buildup of excessive scar tissue — are sounding the alarm in the biotech sector. A silent epidemic creeping up on the Western world involves non-alcoholic...
Attacking All Angles Of Alzheimer’s

Attacking All Angles Of Alzheimer’s

Alzheimer’s Pipeline Roundup Alzheimer’s disease ranks as one of the toughest nuts to crack within drug discovery and development. Current treatments merely manage symptoms, so finding a better solution becomes more and more urgent as the aging population grows....